Exchange: NASDAQ·Updated 07:34 PM EDT
News
all
press releases
Veracyte (VCYT) Q2 Earnings and Revenues Surpass Estimates
Veracyte (VCYT) delivered earnings and revenue surprises of +25.58% and +4.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Analysts Estimate TransMedics (TMDX) to Report a Decline in Earnings: What to Look Out for
TransMedics (TMDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Earnings Preview: Veracyte (VCYT) Q2 Earnings Expected to Decline
Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
RxSight (RXST) Surges 6.1%: Is This an Indication of Further Gains?
RxSight (RXST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks
VCYT Crosses Above Average Analyst Target
In recent trading, shares of Veracyte Inc (Symbol: VCYT) have crossed above the average analyst 12-month target price of $58.27, changing hands for $59.51/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuati...
Nasdaq News: Markets
This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Wall Street analysts initiated coverage on various top stocks, including VCYT, UMAC, FISN, LTRX, and TNGX with positive ratings and price targets.read more...
Benzinga
Alcon & RxSight Collaborate to Develop Adjustable PCIOL Technology
ALC is developing adjustable presbyopia-correcting lenses that pair advanced optics with post-surgery light adjustment.
Zacks
Resmed Divests MatrixCare Business to Sharpen Focus on Connected Care
RMD's MatrixCare sale sharpens its focus on sleep, breathing and connected care while freeing resources for AI-powered digital health.
Zacks
NTRA's Signatera Gains EU IVDR Certification for Multiple Cancers
Natera's Signatera became the first personalized MRD test for solid tumors to earn EU IVDR certification, supporting broader expansion across Europe.
Zacks
Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second quarter 2026 after the close of market on Thursday, July 30, 2026. Company management will host a conference call and webcast to discuss financial results and...
Business Wire

Advertisement|Remove ads.